摘要
目的探索曲美他嗪用于治疗缺血性心肌病心力衰竭(简称心衰)的临床疗效,分析其对患者心功能及心率变异性的影响。方法将76例缺血性心肌病心衰患者按就诊顺序随机分为两组,对照组38例患者采用常规抗心衰治疗,观察组38例患者在常规治疗的同时加用盐酸曲美他嗪片治疗。比较两组临床疗效及治疗前后心功能和心率变异性指标的变化。结果观察组治疗总有效率为94.74%,显著高于对照组的76.32%,差异有统计学意义(χ2=9.76,P<0.05)。治疗后,观察组患者左室舒张末径(LVEDd)和左室收缩末径(LVESd)分别为(58.26±5.67)mm和(44.21±4.83)mm,与对照组比较显著降低(t=6.32,6.76,P<0.05),而左室射血分数(LVEF)和每搏输出量(SU)分别为(46.21±5.07)%和(72.43±6.87)m L,与对照组比较显著升高(t=6.56,7.04,P<0.05);观察组患者24 h内所有正常R-R间期标准差(SDNN),24 h内连续5 min平均正常R-R间期标准差(SDANN),24 h内相邻2个正常R-R间期差值大于50 ms的心搏数占所有心搏数的百分比(PNN50),24 h内相邻正常RR间期差值的均方根值(RMSSD)分别为(125.64±17.26)ms,(113.47±14.75)ms,(20.11±5.66)%,(46.47±10.36)ms,均较对照组显著增加,差异具有统计学意义(t=8.04,7.59,7.44,7.81,P<0.05)。结论曲美他嗪治疗缺血性心肌病心衰的疗效显著,对患者心脏功能和心率变异性各项指标的改善较为明显,值得临床推广。
Objective To investigate the clinical efficacy of trimetazidine for ischemic cardiomyopathy heart failure and its effect on car-diac function and heart rate variability. Methods 76 cases of patients with ischemic cardiomyopathy heart failure were randomly divided into two groups. 38 cases in the control group were treated with conventional anti heart failure treatment, while the observation group of 38 patients used Trimetazidine Hydrochloride Tablets on the basis of the conventional treatment. The clinical efficacy and the changes of heart function and heart rate variability index before and after treatment of the two groups were compared. Results The total effective rate of the observation group was 94. 74%, which was significantly higher than 76. 32% of the control group, the difference was statisti-cally significant （χ2=9. 76, P 〈 0. 05 ） . After treatment, the LVEDd, LVEDd of the observation group were （ 58. 26 ± 5. 67 ） mm and （ 44. 21 ± 4. 83 ） mm, which were significantly lower than the control group （ t=6. 32, 6. 76, P 〈 0. 05 ） , and LVEF and SU were （ 46. 21 ± 5. 07 ）% and （ 72. 43 ± 6. 87 ） mL, which were significantly higher than the control group （ t=6. 56, 7. 04, P 〈 0. 05 ）; the SDNN, SDANN, RMSSD and PNN50 of the observation group were （ 125. 64 ± 17. 26 ） ms, （ 113. 47 ± 14. 75 ） ms, （ 20. 11 ± 5. 66 ）%, （ 46. 47 ± 10. 36 ） ms, which were significantly increased compared with the control group, the difference was statistically significant （ t=8. 04, 7. 59, 7. 44, 7. 81, P 〈 0. 05 ） . Conclusion The clinical efficacy of trimetazidine for heart failure in ischemic cardiomyopathy is significant, the heart function and heart rate variability index improvement is more obvious, and it is worthy of clinical promotion.
出处
《中国药业》
CAS
2016年第19期23-25,共3页
China Pharmaceuticals
关键词
曲美他嗪
缺血性心肌病
心力衰竭
心率变异性
trimetazidine
ischemic cardiomyopathy
heart failure
heart rate variability
